Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...

Novo Nordisk's next-gen obesity drug, CagriSema, faces trial challenges with dosage flexibility and trial length as side-effects remain controlled. Investor skepticism arose from weaker-than-expected ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

So far, Retatrutide, developed by Eli Lilly, has achieved an efficacy rate of 24%, ahead of CagriSema. Previously, the biggest challenge facing Novo Nordisk and Eli Lilly — beyond their rivalry — was ...

When it comes to weight loss drugs ... The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase ...

The FDA has not approved weight loss patches because no evidence of their effectiveness and safety is available. As the FDA does not control these products, it does not regulate the quantity or ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the ... I have no business relationship with any company ...

A big catalyst for the stock could come in June when the company is expected to provide more detailed clinical results for CagriSema, its next-generation weight loss drug. Investors were ...